FAS shRNA treatment reduces the secretion of vascular endothelial growth factor (VEGF) and angiogenesis in breast cancer CA1d cells, leading to reduced tumor growth and a dormant-like phenotype in vivo (Gonzalez-Guerrico et al., 2016). The gene discussed is VEGFA; the disease is breast carcinoma.